STUDYID|DOMAIN|USUBJID|DDSEQ|DDORRES|DDSTRESC|DDRESCAT|DDDTC|DDDY
Study ID|DD|bc1b5635-3292-4053-8401-e257c00b5db2|1|[?]|[?]|UNDETERMINED|2022-05-09|252
Study ID|DD|5b2e3107-b84c-43dc-a5fc-43f02e7def1c|1|[?]|[?]|UNDETERMINED|2021-12-01|36
Study ID|DD|326bc136-7ef2-48a6-bf25-72481da70ba6|1|[?]|[?]|UNDETERMINED|2021-11-03|71
Study ID|DD|528a5210-4439-40ce-a1e7-0597f7aa9350|1|[?]|[?]|UNDETERMINED|2021-10-11|18
Study ID|DD|0fb43761-7a6d-436f-8bcf-cf2d3ace4f9d|1|[?]|[?]|TREATMENT RELATED|2022-04-28|258
Study ID|DD|b3117024-d79c-4ba6-bc57-cd5e32352abb|1|[?]|[?]|NONTREATMENT RELATED|2022-05-06|220
Study ID|DD|25c04c0b-c392-474c-a3d5-82711041ca1e|1|[?]|[?]|ACCIDENTAL|2022-07-10|256
Study ID|DD|2baf42c1-e2c2-46e7-b559-a4f27dde2a62|1|[?]|[?]|UNDETERMINED|2022-02-22|167
Study ID|DD|1325428d-d272-4950-9588-27dac0f58b2d|1|[?]|[?]|NONTREATMENT RELATED|2022-04-25|179
Study ID|DD|4aa4833b-07b3-4f10-be23-98d8449b562c|1|[?]|[?]|TREATMENT RELATED|2022-04-14|195
Study ID|DD|14e47c8e-f157-4202-b16f-563957d7c7ca|1|[?]|[?]|UNDETERMINED|2022-01-12|112
Study ID|DD|ac6bb1a4-5711-4732-ab1e-ab8c7bcad0ef|1|[?]|[?]|TREATMENT RELATED|2022-07-05|299
Study ID|DD|e977fe2e-6626-4c88-8a05-d37f88c10df4|1|[?]|[?]|ACCIDENTAL|2021-10-31|9
Study ID|DD|3e684a59-b5ac-4730-a2fe-13595dc2c8a6|1|[?]|[?]|TREATMENT RELATED|2022-07-02|251
Study ID|DD|e1409bdb-3da1-43e3-bfd5-910e263b4451|1|[?]|[?]|NONTREATMENT RELATED|2022-03-28|179
Study ID|DD|fcc5702d-44d6-4ffc-b81c-b121c1b058a9|1|[?]|[?]|ACCIDENTAL|2022-06-11|261
Study ID|DD|df209108-bad2-4312-a372-1ca91d659760|1|[?]|[?]|NONTREATMENT RELATED|2022-03-01|143
Study ID|DD|32af130e-ded7-42b0-80d2-ef2ab8cb3716|1|[?]|[?]|NONTREATMENT RELATED|2021-11-10|55
Study ID|DD|abf73edd-8476-43ac-8c86-b12ec46cc06f|1|[?]|[?]|TREATMENT RELATED|2021-11-18|40
Study ID|DD|5a60ad4c-9966-47d1-9418-9f9cb058d026|1|[?]|[?]|UNDETERMINED|2021-09-17|17
Study ID|DD|2d16c162-8f9f-4753-a06f-406c60f8bd9a|1|[?]|[?]|UNDETERMINED|2021-10-31|15
